Download PDF
Thromb Haemost 1974; 32(01): 171-188
DOI: 10.1055/s-0038-1647683
Original Article
Schattauer GmbH

Comparative Effects of Proteinase Inhibitors, Plasminogen Antiactivators, Heparin and Acetylsalicylic Acid on the Experimental Disseminated Intravascular Coagulation Induced by Thrombin

M Moriau
1   Laboratory for Haemostasis and Thrombosis Research, University of Louvain, Louvain, Belgium
,
J Rodhain   *
1   Laboratory for Haemostasis and Thrombosis Research, University of Louvain, Louvain, Belgium
,
H Noel   **
1   Laboratory for Haemostasis and Thrombosis Research, University of Louvain, Louvain, Belgium
,
C De Beys-Col
1   Laboratory for Haemostasis and Thrombosis Research, University of Louvain, Louvain, Belgium
,
R Masure
1   Laboratory for Haemostasis and Thrombosis Research, University of Louvain, Louvain, Belgium
› Author Affiliations
Further Information

Publication History

Received: for publication 04 January 1974

Accepted: for publication 02 May 1974

Publication Date:
24 July 2018 (online)

    Permissions and Reprints

Summary

In an experimental study in the rabbit, the modifications of some haemostasis parameters (platelet count, platelet retention and aggregation, platelet factors 3 and 4, platelet and plasma plasmin inhibiting activities, fibrinogen and other plasma factor levels, FDP), and histological findings are compared in both the normal animal and the animal with disseminated intravascular coagulation (DIC) induced by thrombin perfusion after administration of fibrinolytic inhibitors (plasminogen antiactivators and proteinase inhibitors).

In the normal animal, the administration of fibrinolytic inhibitors is followed by haemostatic changes similar to those found in thrombophilic states. The modifications are more pronounced with plasminogen antiactivators than with proteinase inhibitors.

In the animal with DIC, the administration of fibrinolytic inhibitors enhances the haemostatic and the biological disorders produced by thrombin perfusion. The effect of the plasminogen antiactivators is even more evident.

The preventive administration of heparin reduces or abolishes the biological and histological disorders induced by thrombin; its beneficial effect is considerably reduced when thrombin is combined with fibrinolytic inhibitors.

The administration of acetylsalicylic acid appears to be ineffective for the prevention of haemostatic and histological changes induced by thrombin perfusion.

* Laboratory for Haematology (Louvain).


** Laboratory for Pathology (Lou vain).


 

  • References

  • 1 Alkjaersig N, Fletcher A. P, Sherry S. 1959; Epsilon-aminocaproic acid: an inhibitor of plasminogen activation. Journal of Biological Chemistry 234: 832.
    PubMedGoogle Scholar
  • 2 Ambrus C. M, Ambrus J. L, Lassman H. B, Mink I. B. 1968; Studies on the mechanism of action of inhibitors of the fibrinolysin system. Annals of the New York Academy of Sciences 146: 430.
    CrossrefPubMedGoogle Scholar
  • 3 Amris C. J, Hilden M. 1968; Anticoagulant effects of Trasylol, in vitro and in vivo studies. Annals of the New York Academy of Sciences 146: 612.
    CrossrefPubMedGoogle Scholar
  • 4 Andrassy K, Ritz E, Schoeffner W, Hahn G, Walter K. 1971; The influences of acetylsalicylic acid on platelet adhesiveness and thrombotic fistula complications in hemodialysed patients. Klinische Wochenschrift 49: 166.
    CrossrefPubMedGoogle Scholar
  • 5 Back N, Wilkens H, Steger B. 1968; Proteinases and proteinase inhibitors in experimental shock states. Annals of the New York Academy of Sciences 146: 491.
    CrossrefPubMedGoogle Scholar
  • 6 Beller F. K, Mitchell P. S, Gorstein F. 1967; Fibrin deposition in the rabbit kidney produced by protease inhibitors. Thrombosis et Diathesis Haemorrhagica 17: 427.
    PubMedGoogle Scholar
  • 7 Bennett B, Ogston D. 1973; Natural and drug induced inhibitors of fibrinolysis. Clinics in Haematology 02: 135.
    PubMedGoogle Scholar
  • 8 Biggs R, Denson K WE, Akman N, Borrett R, Haddon M. E. 1970; Antithrombin III, antifactor Xa and heparin. British Journal of Haematology 19: 283.
    CrossrefPubMedGoogle Scholar
  • 9 Born G VR, Cross M. J. 1963; The aggregation of blood platelet. Journal of Physiology 168: 178.
    CrossrefPubMedGoogle Scholar
  • 10 Breddin K, Scharrer I, Schepping M. 1970; Acetylsalicylic acid and platelet function. Thrombosis et Diathesis Haemorrhagica 42: 241.
    PubMedGoogle Scholar
  • 11 Breddin K. 1971; Discussion of “Inhibition of platelet aggregation by chemicals and drugs”. Acta Medica Scandinavica supplementum 525: 224.
    PubMedGoogle Scholar
  • 12 Brodsky I, Siegel N. H. 1970; The diagnosis and treatment of disseminated intravascular coagulation. The Medical Clinics of North America 54: 555.
    CrossrefPubMedGoogle Scholar
  • 13 Bützow G. H, Lindner J, Zaki I. 1972. Experimental shock and its treatment with Trasylol. In: Brendel W, Haberland G. L. (eds.) New Aspects of Trasylol Therapy. F. K. Schattauer Yerlag Stuttgart-New York; 245.
    Google Scholar
  • 14 Charytan C. h, Purtilo D. 1969; Glomerular capillary thrombosis and acute renal failure after epsilon aminocaproic acid therapy. New England Journal of Medicine 280: 1102.
    CrossrefPubMedGoogle Scholar
  • 15 Danese C. A, Voleti C. D, Weiss H. J. 1971; Protection by Aspirin against experimentally induced arterial thrombosis in dogs. Thrombosis et Diathesis Haemorrhagica 25: 288.
    PubMedGoogle Scholar
  • 16 Duckert F. 1968; Le syndrome de defibrination. Coagulation 01: 7.
    PubMedGoogle Scholar
  • 17 Feissly R, ET MLudin. 1949; Microscopie par contraste de phase. Application à l’hématologie. Revue d’hématologie 04: 481.
    PubMedGoogle Scholar
  • 18 Fitzgerald D. E, Szeto I. L.f, Spero L, Lewis J. H. 1967; The thrombolytic effect of heparin and heparin-like substance SP 54. Thrombosis et Diathesis Haemorrhagica 17: 418.
    PubMedGoogle Scholar
  • 19 Gans H. 1966; Thrombogenic properties of epsilonaminocaproic acid. Annals of Surgery 163: 175.
    CrossrefPubMedGoogle Scholar
  • 20 Gralnick H. R, Greipp P. 1971; Thrombosis with epsilon-aminocaproïc acid therapy. American Journal of Clinical Pathology 56: 151.
    CrossrefPubMedGoogle Scholar
  • 21 Gram H. C. 1921; A new method for determination of the fibrin percent in blood and plasma. Journal of Biological Chemistry 49: 279.
    PubMedGoogle Scholar
  • 22 Green D, Seeler R. A, Allen N, Alasi I. A. 1972; The role of heparin in the management of consumption coagulopathy. The Medical Clinics of North America 56: 193.
    CrossrefPubMedGoogle Scholar
  • 23 Hajjar G. C, Moser K. M. 1962; Heparin fibrinolytic synergism in vivo. Clinical Research 10: 26.
    PubMedGoogle Scholar
  • 24 Hardaway R. M. 1971; Disseminated intravascular coagulation. Thrombosis et Diathesis Haemorrhagica suppl. 46: 209.
    PubMedGoogle Scholar
  • 25 Harker L. A, Slichter S. J. 1970; Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. New England Journal of Medicine 283: 1302.
    CrossrefPubMedGoogle Scholar
  • 26 Hellem A. J. 1970; Platelet adhesiveness in von Willebrand’s disease. Scandinavian Journal of Haematology 07: 374.
    PubMedGoogle Scholar
  • 27 Hey D, Langer P. 1972. Effects and side effects of the use of heparin, plasmin, epsilon-aminocaproic acid and Trasylol in scalding shock. In: Brendel W, Haberland G. L. (eds.) New Aspects of Trasylol Therapy. F. K. Schattauer Verlag Stuttgart; New-York: 271.
    Google Scholar
  • 28 Hjort P. C. 1966; Continous hemostasis and continous intravascular clotting: Fact or Myth. Thrombosis et Diathesis Haemorrhagica suppl. 20: 15.
    PubMedGoogle Scholar
  • 29 Jerushalmy Z, Sandbank U, Aschheim C, De Vries A. 1970; Disseminated intravascular coagulation in the rabbit induced by Echis carinatus venom. Enhancement of fibrin deposition by epsilon-aminocaproic acid. Coagulation 03: 267.
    PubMedGoogle Scholar
  • 30 Kher A. 1973; Place de l’inhibiteur polyvalent des protéases dans le traitement des états de choc. Médecine Interne 08: 227.
    PubMedGoogle Scholar
  • 31 Kwaan H. C. 1972; Disorders of fibrinolysis. The Medical Clinics of North America 56: 163.
    CrossrefPubMedGoogle Scholar
  • 32 Larcan A, Lambert H, Alexandre P. 1973; Les coagulopathies de consommation. Revue du Praticien 23: 1589.
    PubMedGoogle Scholar
  • 33 Lasch H. G, Heene D. L, Huth K, Sandritter W. 1967; Pathophysiology, clinical manifestations and therapy of consumption coagulopathy. American Journal of Cardiology 20: 381.
    CrossrefPubMedGoogle Scholar
  • 34 Lasch H. G. 1969; Therapeutic aspects of disseminated intravascular coagulation. Thrombosis et Diathesis Haemorrhagica suppl. 36: 281.
    PubMedGoogle Scholar
  • 35 MacDonald A, Busch G. J, Alexander J. L, Pheteplace E. A, Menzoian Y, Murray J. E. 1970; Heparin and aspirin in the treatment of hyperacute rejection of renal allografts in presensitized dogs. Transplantation 09: 1.
    CrossrefPubMedGoogle Scholar
  • 36 McKay D. G. 1965. Disseminated Intravascular Coagulation. New York: Hoeber Medical Division; Harper and Row..
    Google Scholar
  • 37 McKay D. G. 1969; Tissue damage in disseminated intravascular coagulation. Mechanism of localization of thrombi in the microcirculation. Thrombosis et Diathesis Haemorrhagica suppl. 36: 67.
    PubMedGoogle Scholar
  • 38 McNicol G. P, Douglas A. S. 1972. Thrombolytic therapy and fibrinolytic inhibitors. In: Biggs R. (ed.) Human Blood Coagulation, Haemostasis and Thrombosis. Blackwell Scientific Publications; Oxford, London, Edinburgh, Melbourne: 393.
    Google Scholar
  • 39 Mancini G, Carbonara A, Heremans J. F. 1965; Immunochemical quantitation of antigen by single radial immunodiffusion. Immunochemistry 02: 235.
    CrossrefPubMedGoogle Scholar
  • 40 Massion W. H, Blümel G, Peschl L. 1972. The role of proteolytic enzymes in refractory hypotention. In: Brendel W, Haberland G. L. (eds.) New Aspects of Trasylol Therapy. F. K. Schattauer Verlag; Stuttgart, New York: 73.
    Google Scholar
  • 41 Merskey C, Johnson A. J, Pert Y, Wohl H. 1964; Pathogenesis of fibrinolysis in defibrination syndrome, effect of heparin administration. Blood 24: 701.
    PubMedGoogle Scholar
  • 42 Merskey C, Johnson A. J, Kleiner G. J, Wohl H. 1967; The defibrination syndrome. Clinical feature and laboratory diagnosis. British Journal of Haematology 13: 528.
    PubMedGoogle Scholar
  • 43 Merskey C. 1972. Defibrination syndrome. In: Biggs R. (eds.) Human Blood Coagulation Haemostasis and Thrombosis. Blackwell Scientific Publications: Oxford, London, Edinburgh, Melbourne; 444.
    Google Scholar
  • 44 Merskey C. 1973; Defibrination syndrome . ? Blood 41: 599.
    PubMedGoogle Scholar
  • 45 Moriau M. 1969; Inhibiteurs naturels de la fibrinolyse et phénomènes thrombohé- morragiques. Pathologia europaea, 4 suppl. 01: 1.
    PubMedGoogle Scholar
  • 46 Mühe E, von Der Emde J, Raithel D. 1971; Zur Prophylaxe der Thrombozytenaggregation an künstlichen Herzklappen durch Azetylsalizylsäure. Medizinische Welt 35: 1335.
    PubMedGoogle Scholar
  • 47 Mustard J. F, Kinlough R. L, Rathbone C, Jenkins S. P, Packam M. A. 1972; Modification of platelet function. Annals of the New York Academy of Sciences 201: 343.
    CrossrefPubMedGoogle Scholar
  • 48 Naeye R. L. 1962; Thrombotic state after a haemorrhagic diathesis, a possible complication of therapy with epsilon-aminocaproic acid. Blood 06: 694.
    PubMedGoogle Scholar
  • 49 Nilsson I. M, Sjoerdsma A, Waldenstrom J. 1960; Antifibrinolytic activity and metabolism of EACA in man. Lancet i: 1322.
    PubMedGoogle Scholar
  • 50 Nordstrom S. 1970; Effects of fibrinolytic inhibitors and heparin on induced intravascular coagulation. Acta physiologica scandinavica suppl. 337: 7.
    PubMedGoogle Scholar
  • 51 Nordstrom S, Zetterqvist E. 1968; Effects of epsilon-aminocaproic acid (EACA) and Trasylol on thromboplastin induced intravascular coagulation studied in dogs with iodine - labelled fibrinogen. Acta physiologica scandinavica 76: 1.
    PubMedGoogle Scholar
  • 52 O’Brien J. R. 1960; The effect of heparin on the early stages of blood coagulation. Journal of Clinical Pathology 13: 93.
    CrossrefPubMedGoogle Scholar
  • 53 O’Brien J. R. 1968; Effect of antiinflammatory agents on platelets. Lancet i: 894.
    PubMedGoogle Scholar
  • 54 O’Brien J. R, Finch W, Clark E. 1970; A comparison of an effect of different antiinflammatory drugs on human platelets. Journal Clinical Pathology 23: 522.
    PubMedGoogle Scholar
  • 55 O’Brien J. R. 1971; Antiinflammatory drugs and the prevention of thrombosis. Acta Medica Scandinavica suppl. 525: 211.
    PubMedGoogle Scholar
  • 56 O’Brien J. R, Tulevski V, Etherington M. 1971; Two in vivo studies comparing high and low aspirin dosage. Lancet i: 399.
    PubMedGoogle Scholar
  • 57 Okamoto S, Oshiba S, Mihara H, Okamoto U. 1968; Synthetic inhibitors of fibrinolysis in vitro and in mode of action. The Annals of the New York Academy of Sciences 146: 414.
    PubMedGoogle Scholar
  • 58 Peterson J, Zucker M. B. 1970; The effect of adenosine monophosphate, arcaine, and antiinflammatory agents on thrombosis and platelet functions in rabbits. Thrombosis et Diathesis Haemorragica 23: 148.
    PubMedGoogle Scholar
  • 59 Pitney W. R. 1971; Disseminated intravascular coagulation. Seminars in Haematology 08: 65.
    PubMedGoogle Scholar
  • 60 Puchtler H, Sweat F, Doos N. O. 1963; A one hour phosphotungstic acid hematoxylin stain. American Journal of Clinical Pathology 40: 334.
    CrossrefPubMedGoogle Scholar
  • 61 Raby C. 1970. Coagulation intravasculaires disséminées et localisées. Masson et Cie; Paris.:
    Google Scholar
  • 62 Ratnoff O. D. 1969; Epsilon-aminocaproic acid. A dangerous weapon. New England Journal of Medicine 280: 1124.
    PubMedGoogle Scholar
  • 63 Salzman E. W, Harris W. H, De Sanctis R. W. 1971; Reduction in venous thromboembolism by agents affecting platelet function. New England Journal of Medicine 284: 1287.
    CrossrefPubMedGoogle Scholar
  • 64 Thomas D. P. 1972. Drug therapy of venous throembolism. In: Kakkar V, Joukar A. J. (eds.) Thromboembolism : Diagnosis and Treatment. Churchill-Livingstone; 155.
    Google Scholar
  • 65 Yermeylen J, De Gaetano G-, Verstraete M. 1973. Platelet and Thrombosis. In: Poller L. (ed.) Recent Advances in Thrombosis. Churchill Livingstone; Edinburgh and London: 113.
    Google Scholar
  • 66 von Franken L, Johannsson L, Olsson P. I, Zetterqvist E. 1963; Heparin treatment of bleeding due to primary hypercoagulability. Journal of Cardiovascular Surgery 04: 650.
    PubMedGoogle Scholar
  • 67 Weiss H. J, Aledort L. M, Kochwa S. 1968; The effect of salicylates on the hemostatic properties of platelets in man. Journal of Clinical Investigation 47: 2169.
    CrossrefPubMedGoogle Scholar
  • 68 Weiss H. J, Danese C. A, Voleti C. D. 1970; Prevention of experimentally induced arterial thrombosis by aspirin. Federation Proceedings 29: 381.
    PubMedGoogle Scholar
  • 69 Yin E. T, Wessler S. 1970; Heparin accelerated inhibition of activated factor X by its natural plasma inhibitor. Biochemica et Biophysica Acta 201: 387.
    CrossrefPubMedGoogle Scholar
  • 70 Zucker M. B, Peterson J. 1970; Effect of acetylsalicylic acid, other non steroidal antiinflammatory agents and dipyridamole on human blood platelets. Journal of Laboratory and Clinical Medicine 76: 66.
    PubMedGoogle Scholar